Atea raises $215M to support midphase COVID-19 antiviral trial 

Atea CEO Jean-Pierre Sommadossi (Atea Pharmaceuticals)

Bain Capital Life Sciences has powered Atea Pharmaceuticals to a $215 million financing round. The series D sets Atea up to run a phase 2 trial of its oral purine nucleotide prodrug in people hospitalized with moderate cases of COVID-19.

Jean-Pierre Sommadossi, co-founder of Sovaldi-developer Pharmasset, created Atea in 2014 to work on treatments for viral diseases. Atea raised close to $70 million across three rounds and ran a clutch of phase 1 and 2 trials in hepatitis C over the following years, without ever establishing itself as a big name in biotech. That is about to change.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Wednesday, investors including Bain, RA Capital Management and Perceptive Advisors put Atea on the map with a mega-round that will fund work to reposition hepatitis C candidate AT-527 for use in the treatment of COVID-19.

Atea disclosed the financing on the same day it posted a ClinicalTrials.gov listing for a phase 2 trial that will test AT-527 in 180 people hospitalized with moderate COVID-19. The trial is designed to find out whether AT-527 is better than placebo at stopping patients from progressing to respiratory failure. Given the unmet need, a rapid route to market is possible.

While Atea originally tested AT-527 in hepatitis C patients, the biotech thinks the molecule’s ability to interfere with viral RNA polymerase, thereby inhibiting replication, may make it effective against SARS-CoV-2. Atea has internal in vitro data on the activity of AT-527 against human coronaviruses to back up its hypothesis.

The series D will enable Atea to test that hypothesis in a phase 2 trial that is scheduled to start this month and has an estimated primary completion date in July. Initiating the trial marks a milestone in Atea’s pivot to COVID-19. 

“We have shifted all of our immediate resources and our team’s deep expertise in virology and pharmacology to help address the unmet needs in the fight against the COVID-19 pandemic. An oral treatment for COVID-19 patients should prevent progression of the disease and may help lessen the burden on critical inpatient resources,” Atea CEO Sommadossi said in a statement.

The shift to COVID-19 and fallout from the pandemic has affected some of Atea’s other programs. While work on treatments for dengue and respiratory syncytial virus is continuing, development of three hepatitis C programs has been delayed by the pandemic. Atea plans to use some of the series D money to fund its non-COVID-19 programs.

Suggested Articles

Bayer strengthened its ties with Scottish AI developer Blackford Analysis to build a one-stop shop for applications in medical imaging.

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Boston Scientific has moved to hive off the specialty pharmaceuticals division it picked up through last year’s $4.2 billion acquisition of BTG.